XML 25 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating activities      
Net loss $ (169,142) $ (74,617) $ (81,452)
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation 70,844 10,124 9,889
Depreciation and amortization 10,607 3,993 4,764
Amortization of deferred contract costs 5,030 3,648 2,266
Amortization of debt discount and issuance costs 1,390 0 0
Interest on discount on convertible note 0 0 1,248
Amortization of operating lease right-of-use assets 3,207 2,354 0
Release of valuation allowance and change in deferred taxes (39,311) 0 0
Other 2,944 719 288
Changes in operating assets and liabilities:      
Trade and other receivables (5,839) (12,171) 301
Prepaid expenses and other assets, current and non-current (13,929) (6,539) (7,133)
Deferred contract costs, non-current 1,236 (2,042) (845)
Accounts payable 1,558 293 2,583
Deferred revenue (5,554) 1,226 5,727
Accrued compensation 5,588 5,725 2,273
Operating lease liabilities (3,200) (2,573) 0
Other liabilities, current and non-current 7,067 4,847 1,152
Net cash used in operating activities (127,504) (65,013) (58,939)
Investing activities      
Purchases of marketable securities (351,583) (173,965) (150,744)
Sales of marketable securities 0 36,746 3,498
Maturities of marketable securities 125,075 130,624 82,353
Purchases of property and equipment (1,734) (1,313) (580)
Investment in non-marketable equity securities (2,500) 0 0
Investment in note receivable (3,000) 0 0
Acquisition of Title365, net of cash acquired (400,014) 0 0
Capitalization of internal-use software (152) 0 0
Purchases of intangible assets 0 (9) (40)
Net cash used in investing activities (633,908) (7,917) (65,513)
Financing activities      
Proceeds from initial public offering, net of underwriters' fees and issuance costs 366,805 0 0
Proceeds from debt financing, net of issuance costs 218,792 0 0
Repurchases of unvested early exercised stock options (131) (18) (52)
Proceeds from exercises of stock options, including early exercises 25,353 4,527 1,648
Proceeds from exercises of common stock warrants 0 10,000 0
Proceeds from issuance of Convertible Preferred Stock, net of issuance costs 309,701 76,247 124,647
Proceeds from exercises of Convertible Preferred Stock warrants 10,172 0 0
Proceeds from repayment of employee promissory note collateralized by common stock 2,881 0 0
Proceeds from convertible debt 0 0 4,990
Proceeds from exercises of Series D Convertible Preferred Stock warrants 0 0 1,500
Other 0 0 (67)
Net cash provided by financing activities 933,573 90,756 132,666
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (9) 0 0
Net increase in cash, cash equivalents, and restricted cash 172,152 17,826 8,214
Cash, cash equivalents, and restricted cash at beginning of period 46,288 28,462 20,248
Cash, cash equivalents, and restricted cash at end of period 218,440 46,288 28,462
Reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheets:      
Cash and cash equivalents 213,082 41,092 22,646
Restricted cash 5,358 5,196 5,816
Total cash, cash equivalents, and restricted cash 218,440 46,288 28,462
Supplemental disclosure of cash flow information:      
Cash paid for income taxes 884 26 8
Cash paid for interest 6,428 0 0
Supplemental disclosure of non-cash investing and financing activities:      
Vesting of early exercised stock options 5,023 210 597
Non-cash additions to property and equipment 0 1,347 0
Operating lease liabilities arising from obtaining new or modified right-of-use assets 1,715 1,398 0
Accretion adjustments of redeemable noncontrolling interest to redemption value 1,430 0 0
Issuance of warrant in connection with debt financing 6,789 0 0
Exercise of Series D Convertible Preferred Stock warrants included in prepaid expenses and other current assets $ 0 $ 2,158 $ 0